Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2014-04-28 |
PROTEVIH consortium : Innavirvax (France), Diaxonhit, INSERM-Université Paris-Sud/CESP / U1018 at Hôpital Kremlin Bicêtre, INSERM-Université de Bordeaux Segalen / ISPED - UMR 897 |
€9.4 million |
subsidies and refundable advance payments |
Bpifrance (France) |
Infectious diseases |
Subvention |
2014-04-28 |
Orca Pharmaceuticals (UK) |
$1.3 million |
financing round |
BioMotiv (USA - OH) |
Autoimmune diseases |
Financing round |
2014-04-25 |
Genalice (The Netherlands) |
undisclosed |
|
Redbrae (UK-USA) |
|
Fundraising |
2014-04-24 |
Isarna Therapeutics (Germany) |
€ 5.5 million |
financing round |
AT NewTec (Germany), Global Asset Funds (Germany), MIG Fonds (Germany) |
Cancer - Oncology |
Financing round |
2014-04-22 |
Pharming (The Netherlands) |
€14.7 million |
private placement |
existing institutional investors |
Rare diseases - Genetic diseases |
Private placement |
2014-04-22 |
Hoopika Biotech (Austria) |
€ 1.64 million + € 3.38 million |
grant |
Austrian Research Promotion Agency (FFG) (Austria) |
Cancer - Oncology - Infectious diseases |
Grant |
2014-04-17 |
Oncobiologics (USA - NJ) |
$ 10 million |
private placement |
|
|
Private placement |
2014-04-16 |
OxThera (Sweden) |
70 MSEK (€7.7 million) |
financing round |
Kurma Partners (France) IdInvest Partners (France) Mayo Clinic (USA) |
Rare diseases - Kidney diseases - Renal diseases |
Financing round |
2014-04-15 |
Mucosis (The Netherlands) |
€ 5 million |
financing round |
Changchun BCHT Biotechnology Co (China), BioGeneration Ventures (The Netherlands), MedSciences Capital (The Netherlands), NV NOM (Investment and Development Agency for the Northern Netherlands) (The Netherlands), Utrecht Holdings (The Netherlands) |
Infectious diseases - Respiratory diseases |
Financing round |
2014-04-15 |
Medgenics (USA - Israel) |
$2.2 Million (€1.6 million) |
grant |
Office of the Chief Scientist (OCS -Israel) |
Rare diseases |
Grant |
2014-04-15 |
AAVLife (France) |
$ 12 million (€ 8.68 million) |
series A financing round |
Versant Ventures (USA) Inserm Transfert Initiative (France) |
Rare diseases - Neurodegenerative diseases |
Series A financing round |
2014-04-14 |
Domain Therapeutics (France) |
$ 230 000 (€166 110) |
grant |
The Michael J. Fox Foundation - MJFF (USA) |
Neurodegenerative diseases |
Grant |
2014-04-14 |
The EFFIMAB consortium (Effimune, PX’Therapeutics, The Nantes Centre for Research in Transplantation and Immunology (CRTI/INSERM UMR 1064) and the Institute for Transplantation-Urology-Nephrology (ITUN), based in Nantes, the University Institute of Hematology (INSERM-UMR944) of the St Louis Hospital in Paris, the Paris Public Welfare Hospital (Assistance Publique–Hôpitaux de Paris), and the Lille Regional University Hospital Centre (CHRU de Lille) |
€9.5 million |
subvention and refundable aids |
Bpifrance (France) |
Autoimmune diseases – Inflammatory diseases - Cancer - Oncology |
Grant |
2014-04-14 |
BloodPharma consortium (the Scottish National Blood Service (UK), Cell Therapy Catapult (UK), NHS Blood and Transplant (UK), Roslin Cells (UK)) |
£5 million (€ 6.04 million) |
grant |
Wellcome Trust (UK) |
|
Grant |
2014-04-11 |
TxCell (France) |
€16.2 million |
IPO |
Auriga Partners (France) Seventure Partners (France) Bpifrance (France) |
Autoimmune diseases – Inflammatory diseases |
IPO |
2014-04-10 |
Nucana (UK) |
$ 57 million (€41 million) |
series B financing round |
Sofinnova Venture (USA) - Sofinnova Partners (France) - Morningside Ventures (China - USA) - Alida Capital International (UK) - Scottish Investment Bank (UK) |
Cancer - Oncology |
Series B financing round |
2014-04-09 |
Quantum Genomics (France) |
€3.4 million |
private placement |
Thétys (France) and other institutional investors |
Cardiovascular diseases |
Private placement |
2014-04-08 |
Biotec Pharmacon (Norway) |
NOK 78 million (€9.47 million) |
private placement |
|
Medical devices |
Private placement |
2014-04-08 |
Piqur Therapeutics (Switzerland) |
CHF 32 million (€ 26.2 million) |
series A financing round |
Versant Ventures (USA) |
Cancer - Oncology |
Series A financing round |
2014-04-07 |
Newron Pharmaceuticals (Italy) |
CHF18.6 million (€15.2 million) |
private placement |
undisclosed institutional shareholders institutional investors joining from Europe and the USA, including J.P. Morgan Asset Management (USA), Aviva (UK), Investor AB (Sweden) and Swisscanto (Switzerland). |
CNS diseases - Neurodegenerative diseases - Rare diseases |
Private placement |